Yu-Shen Yang
Research Subjects
Yu-Shen Yang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Dan Wen
Department of General Surgery, Dalian University Affiliated Xinhua Hospital, Dalian, China
2 shared publications - Xue-Feng Zhao
Department of General Surgery, Dalian University Affiliated Xinhua Hospital, Dalian, 116021, China
2 shared publications Chu-Yun Liu
Affiliation Department of Anesthesiology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China
1 shared publication- Chu-Yun Mm Liu
Department of Anesthesiology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China
1 shared publication - D. Z. Gao
Department of Medical Imaging, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China
1 shared publication Gao-Fang Wu
Affiliation Department of Anesthesiology, Shishi General Hospital, Quanzhou, China
1 shared publication
Latest Publications
- Open Access
- 19 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0338591
Multi-omics analysis identifies PPARα as a key inhibitor of hepatocyte ferroptosis in sepsis-associated liver injury
Background: Sepsis-associated liver injury (SLI) increases the risk of death in septic patients, and a primary pathological alteration in sepsis is ferroptosis in the liver. However, the specific mechanism of its occurrence remains largely unclear. Our work is to validate key pathways connected with ferroptosis in SLI and elucidate potential pharmaceutical targets involved in this process. Methods: To confirm targets related to SLI, we screened three SLI microarray datasets (GSE23767, GSE40180 and GSE104342) from the GEO database and obtained the ferroptosis-related differentially expressed genes (FRDEGs). A functional enrichment analysis of FRDEGs was performed. The protein–protein interaction network was used to visualize the interactive relationship of FRDEGs. Additionally, the potential biological functions and enrichment pathways of FRDEGs were elucidated through GO and KEGG analysis. Furthermore, we obtained the single-cell dataset (GSE238000) from liver tissue from GEO database to determine the series of cell subtype mainly expressing target molecules. Finally, we performed a serial of in vivo and in vitro experiments to further validate the findings of bioinformatic analysis. Results: A total of 51 genes that are expressed differently in SLI involve ferroptosis. These genes are involved in negative regulation of apoptotic process, the endoplasmic reticulum, and identical protein binding. The KEGG pathway study revealed that they were mainly involved in the PPAR signaling pathway. Among three isoforms of PPAR family, PPARα is most abundant in the liver. We then observed that it was significantly downregulated in hepatic tissue of SLI mice and PPARα agonist WY-14643 effectively blocked sepsis-induced hepatic ferroptosis. Subsequently, single-cell analysis demonstrated that PPARα is predominantly expressed in hepatocytes, which was downregulated in LPS-treated THLE-2 cells. Notably, consistent with the in vivo results, PPARα activator WY-14643 also significantly alleviated LPS-induced ferroptosis in THLE-2 cells. Conclusion: The validation of ferroptosis-related pathway PPARα in this study greatly deepens our understanding of the potential mechanism of SLI, and provide promising therapeutic targets for the disease.
- 19 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0338591
Open AccessMulti-omics analysis identifies PPARα as a key inhibitor of hepatocyte ferroptosis in sepsis-associated liver injury
Background: Sepsis-associated liver injury (SLI) increases the risk of death in septic patients, and a primary pathological alteration in sepsis is ferroptosis in the liver. However, the specific mechanism of its occurrence remains largely unclear. Our work is to validate key pathways connected with ferroptosis in SLI and elucidate potential pharmaceutical targets involved in this process. Methods: To confirm targets related to SLI, we screened three SLI microarray datasets (GSE23767, GSE40180 and GSE104342) from the GEO database and obtained the ferroptosis-related differentially expressed genes (FRDEGs). A functional enrichment analysis of FRDEGs was performed. The protein–protein interaction network was used to visualize the interactive relationship of FRDEGs. Additionally, the potential biological functions and enrichment pathways of FRDEGs were elucidated through GO and KEGG analysis. Furthermore, we obtained the single-cell dataset (GSE238000) from liver tissue from GEO database to determine the series of cell subtype mainly expressing target molecules. Finally, we performed a serial of in vivo and in vitro experiments to further validate the findings of bioinformatic analysis. Results: A total of 51 genes that are expressed differently in SLI involve ferroptosis. These genes are involved in negative regulation of apoptotic process, the endoplasmic reticulum, and identical protein binding. The KEGG pathway study revealed that they were mainly involved in the PPAR signaling pathway. Among three isoforms of PPAR family, PPARα is most abundant in the liver. We then observed that it was significantly downregulated in hepatic tissue of SLI mice and PPARα agonist WY-14643 effectively blocked sepsis-induced hepatic ferroptosis. Subsequently, single-cell analysis demonstrated that PPARα is predominantly expressed in hepatocytes, which was downregulated in LPS-treated THLE-2 cells. Notably, consistent with the in vivo results, PPARα activator WY-14643 also significantly alleviated LPS-induced ferroptosis in THLE-2 cells. Conclusion: The validation of ferroptosis-related pathway PPARα in this study greatly deepens our understanding of the potential mechanism of SLI, and provide promising therapeutic targets for the disease.
- Open Access
- 30 September 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (9) , e0310898
Mendelian randomization analysis reveals causal association of anthropometric measures on sepsis risk and mortality
The objective of this study was to explore the potential causalities of fat mass, nonfat mass and height (henceforth, ‘anthropometric measures’) with sepsis risk and mortality. We conducted the Mendelian randomization (MR) investigation using genome-wide association study (GWAS) summary statistics of anthropometric measures, sepsis, and sepsis mortality. The GWAS summary data from the UK Biobank was used. Firstly, MR analysis was performed to estimate the causal effect of anthropometric measures on the risk of sepsis. The inverse-variance weighted (IVW) method was utilized as the primary analytical approach, together with weighted median-based method. Cochrane’s Q test and MR-Egger intercept test were performed to assess heterogeneity and pleiotropy, respectively. Finally, we performed a series of sensitivity analyses to enhance the precision and veracity of our findings. The IVW method showed that genetically predicted weight-related measures were suggestively linked to an increased risk of sepsis. However, height displayed no causal association with sepsis risk and mortality. Furthermore, weight-related measures also displayed significant MR association with the sepsis mortality, except body nonfat mass and right leg nonfat mass. However, MVMR analysis indicated the observed effects for weight-related measures in the univariable MR analyses are more likely a bias caused by the interrelationship between anthropometric measures. According to the MR-Egger intercept assessment, our MR examination was not influenced by horizontal pleiotropy (all p>0.05). Moreover, the reliability of the estimated causal association was confirmed by the sensitivity analyses. In conclusion, these findings provided vital new knowledge on the role of anthropometric-related measures in the sepsis etiology.
- 30 September 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (9) , e0310898
Open AccessMendelian randomization analysis reveals causal association of anthropometric measures on sepsis risk and mortality
The objective of this study was to explore the potential causalities of fat mass, nonfat mass and height (henceforth, ‘anthropometric measures’) with sepsis risk and mortality. We conducted the Mendelian randomization (MR) investigation using genome-wide association study (GWAS) summary statistics of anthropometric measures, sepsis, and sepsis mortality. The GWAS summary data from the UK Biobank was used. Firstly, MR analysis was performed to estimate the causal effect of anthropometric measures on the risk of sepsis. The inverse-variance weighted (IVW) method was utilized as the primary analytical approach, together with weighted median-based method. Cochrane’s Q test and MR-Egger intercept test were performed to assess heterogeneity and pleiotropy, respectively. Finally, we performed a series of sensitivity analyses to enhance the precision and veracity of our findings. The IVW method showed that genetically predicted weight-related measures were suggestively linked to an increased risk of sepsis. However, height displayed no causal association with sepsis risk and mortality. Furthermore, weight-related measures also displayed significant MR association with the sepsis mortality, except body nonfat mass and right leg nonfat mass. However, MVMR analysis indicated the observed effects for weight-related measures in the univariable MR analyses are more likely a bias caused by the interrelationship between anthropometric measures. According to the MR-Egger intercept assessment, our MR examination was not influenced by horizontal pleiotropy (all p>0.05). Moreover, the reliability of the estimated causal association was confirmed by the sensitivity analyses. In conclusion, these findings provided vital new knowledge on the role of anthropometric-related measures in the sepsis etiology.
- Open Access
- 20 October 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (42) , e35154
Mitophagy-related genes could facilitate the development of septic shock during immune infiltration
Septic shock often occurs following critically low blood pressure in patients with sepsis, and is accompanied by a high death rate. Although mitophagy is associated with infection and immune responses, its role in septic shock remains unknown. This study screened effective mitophagy-related genes (MRGs) for medical practice and depicted immune infiltration situations in patients with septic shock. Gene expression profiles of GSE131761 from the Gene Expression Omnibus database were compiled for differential analysis, weighted gene co-expression network analysis, and immune infiltration analysis, while other GSE series were used as validation datasets. A series of validation methods were used to verify the robustness of hub genes, while a nomogram and prognosis model were established for medical practice. Six genes were screened via combinations of differentially expressed genes, weighted gene co-expression network analysis, and MRGs. From this, 3 hub genes (MAP1LC3B, ULK1, and CDC37) were chosen for subsequent analysis based on different validation methods. Gene set enrichment analysis showed that leukocyte trans-endothelial migration and the p53 signaling pathway were abnormally activated during septic shock. Immune infiltration analysis indicated that the imbalance of neutrophils and CD4 naive T cells was significantly correlated with septic shock progression. A nomogram was generated based on MAP1LC3B, ULK1, and CDC37, as well as age. The stability of our model was confirmed using a calibration plot. Importantly, patients with septic shock with the 3 highly expressed hub genes displayed worse prognosis than did patients without septic shock. MAP1LC3B, ULK1, and CDC37 are considered hub MRGs in the development of septic shock and could represent promising diagnostic and prognostic biomarkers in blood tissue. The validated hub genes and immune infiltration pattern expand our knowledge on MRG functional mechanisms, which provides guidance and direction for the development of septic shock diagnostic and therapeutic markers.
- 20 October 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (42) , e35154
Open AccessMitophagy-related genes could facilitate the development of septic shock during immune infiltration
Septic shock often occurs following critically low blood pressure in patients with sepsis, and is accompanied by a high death rate. Although mitophagy is associated with infection and immune responses, its role in septic shock remains unknown. This study screened effective mitophagy-related genes (MRGs) for medical practice and depicted immune infiltration situations in patients with septic shock. Gene expression profiles of GSE131761 from the Gene Expression Omnibus database were compiled for differential analysis, weighted gene co-expression network analysis, and immune infiltration analysis, while other GSE series were used as validation datasets. A series of validation methods were used to verify the robustness of hub genes, while a nomogram and prognosis model were established for medical practice. Six genes were screened via combinations of differentially expressed genes, weighted gene co-expression network analysis, and MRGs. From this, 3 hub genes (MAP1LC3B, ULK1, and CDC37) were chosen for subsequent analysis based on different validation methods. Gene set enrichment analysis showed that leukocyte trans-endothelial migration and the p53 signaling pathway were abnormally activated during septic shock. Immune infiltration analysis indicated that the imbalance of neutrophils and CD4 naive T cells was significantly correlated with septic shock progression. A nomogram was generated based on MAP1LC3B, ULK1, and CDC37, as well as age. The stability of our model was confirmed using a calibration plot. Importantly, patients with septic shock with the 3 highly expressed hub genes displayed worse prognosis than did patients without septic shock. MAP1LC3B, ULK1, and CDC37 are considered hub MRGs in the development of septic shock and could represent promising diagnostic and prognostic biomarkers in blood tissue. The validated hub genes and immune infiltration pattern expand our knowledge on MRG functional mechanisms, which provides guidance and direction for the development of septic shock diagnostic and therapeutic markers.
- 18 November 2021
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 172 (1) , 26-32
Oridonin Enhances the Anti-Metastasis Effect of Oxaliplatinliplatin on Colorectal Cancer Liver Metastasis
The anti-metastasis effect of oridonin in combination with oxaliplatin on colorectal cancer liver metastasis was studied using a BALB/c nude mouse model. The liver condition, bloody ascites, cholestasis, and liver metastasis scores in the three groups receiving oxaliplatin combined with oridonin were significantly milder than in the control group and importantly the anti-migratory effect of oxaliplatin combined with oridonin was obviously the strongest (p<0.05). Oridonin possessed no hepatotoxicity; instead, it effectively alleviated liver injury caused by oxaliplatin. Oridonin alone or in combination with oxaliplatin significantly decreased serum levels of α-fetoprotein and carcinoembryonic antigen. Therefore, oridonin combined with oxaliplatin displays great potential to markedly increase the anti-metastasis effect of oxaliplatin in the treatment of liver metastases of colorectal cancer.
- 18 November 2021
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 172 (1) , 26-32
Oridonin Enhances the Anti-Metastasis Effect of Oxaliplatinliplatin on Colorectal Cancer Liver Metastasis
The anti-metastasis effect of oridonin in combination with oxaliplatin on colorectal cancer liver metastasis was studied using a BALB/c nude mouse model. The liver condition, bloody ascites, cholestasis, and liver metastasis scores in the three groups receiving oxaliplatin combined with oridonin were significantly milder than in the control group and importantly the anti-migratory effect of oxaliplatin combined with oridonin was obviously the strongest (p<0.05). Oridonin possessed no hepatotoxicity; instead, it effectively alleviated liver injury caused by oxaliplatin. Oridonin alone or in combination with oxaliplatin significantly decreased serum levels of α-fetoprotein and carcinoembryonic antigen. Therefore, oridonin combined with oxaliplatin displays great potential to markedly increase the anti-metastasis effect of oxaliplatin in the treatment of liver metastases of colorectal cancer.
- 6 January 2021
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 394 (6) , 1263-1274
Sophocarpine can enhance the inhibiting effect of oxaliplatin on colon cancer liver metastasis—in vitro and in vivo
To determine whether sophocarpine (SC) can enhance the inhibiting effect of oxaliplatin on colorectal cancer (CRC) liver metastasis (CRCLM)—in vitro and in vivo. The inhibitory effect of SC and/or oxaliplatin on the proliferation, invasion, and migration of CRC cells was determined by CCK-8, MTT, wound healing migration, and transwell assay. Western blot and immunohistochemistry were used to evaluate the inhibitory effect of SC and/or oxaliplatin on the epithelial-mesenchymal transition (EMT) process. Nude mouse models of human CRCLM were established to test the anti-metastasis effect of SC and oxaliplatin in the single or combined form. SC exerted an inhibitory effect on the proliferation, invasion, and migration of CRC cells both in vitro and in vivo. The combination index of SC and oxaliplatin was 0.58. In addition, the inhibitory effect of SC in combination with oxaliplatin was found to be significantly stronger compared with that mediated by either SC or oxaliplatin alone, suggesting that SC can effectively enhance the inhibitory effect of oxaliplatin on CRCLM both in vitro and in vivo. SC was also revealed to reverse EMT process in cell lines and tissues, as reflected by the observed downregulation of N-cadherin and vimentin expression and the upregulation of E-cadherin expression. Taken together, data from the present study suggest that SC administration can inhibit CRC cell proliferation, invasion, migration, and EMT, while enhancing the inhibitory effects of oxaliplatin both in vitro and in vivo. These findings indicate (that) SC to be a promising anti-metastasis agent for CRCLM.
- 6 January 2021
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 394 (6) , 1263-1274
Sophocarpine can enhance the inhibiting effect of oxaliplatin on colon cancer liver metastasis—in vitro and in vivo
To determine whether sophocarpine (SC) can enhance the inhibiting effect of oxaliplatin on colorectal cancer (CRC) liver metastasis (CRCLM)—in vitro and in vivo. The inhibitory effect of SC and/or oxaliplatin on the proliferation, invasion, and migration of CRC cells was determined by CCK-8, MTT, wound healing migration, and transwell assay. Western blot and immunohistochemistry were used to evaluate the inhibitory effect of SC and/or oxaliplatin on the epithelial-mesenchymal transition (EMT) process. Nude mouse models of human CRCLM were established to test the anti-metastasis effect of SC and oxaliplatin in the single or combined form. SC exerted an inhibitory effect on the proliferation, invasion, and migration of CRC cells both in vitro and in vivo. The combination index of SC and oxaliplatin was 0.58. In addition, the inhibitory effect of SC in combination with oxaliplatin was found to be significantly stronger compared with that mediated by either SC or oxaliplatin alone, suggesting that SC can effectively enhance the inhibitory effect of oxaliplatin on CRCLM both in vitro and in vivo. SC was also revealed to reverse EMT process in cell lines and tissues, as reflected by the observed downregulation of N-cadherin and vimentin expression and the upregulation of E-cadherin expression. Taken together, data from the present study suggest that SC administration can inhibit CRC cell proliferation, invasion, migration, and EMT, while enhancing the inhibitory effects of oxaliplatin both in vitro and in vivo. These findings indicate (that) SC to be a promising anti-metastasis agent for CRCLM.